Accelerate drug discovery and development with in silico solutions
Aganitha partners with global pharma to bring novel medicines to market faster. Physics based chemistry, omics enriched biology, generative AI and tech innovations power our offerings.
Transforming biopharma R&D powered by deep science & deep tech
Aganitha is a new generation in silico company that integrates high-throughput sciences with deep learning-based generative models to solve complex drug discovery and development challenges.
Bringing a new drug to market takes $1-2B and 6-12 years. Advances in scRNA, multiomics, long read sequencing, structural biology, first principles based chemistry etc. now allows us to take far less time, at a lower cost and a higher probability of success.
Our services and solutions help drive this transformation with the following foundational elements.
Multiscale Systems Biology
Better Chemistry
Generative AI
Wet lab and in silico virtuous loop for de novo design
Accelerate the design of SMOL and biological molecules by establishing in silico iterative models to predict and optimize physical, chemical, and biological properties in a virtuous loop with in vitro or in vivo data
Platform and Data Approach/Focus
Jumpstart the adoption of AI-powered in silico models with pre-packaged domain specific platforms and solutions for your use cases, with the ability to combine proprietary data with public data sets
Why Aganitha?
Leverage our experience and strengths to build transformational solutions in biopharma
Multi-domain skills
Deep Focus
Solutions foundation
Agile + Enterprise-grade
Client Centric
Client teams: Research + Informatics